What department should I go to for non-invasive DNA testing?

Non-invasive DNA testing is a test that is often performed in obstetrics and gynecology. This test is mainly to check whether the fetus in the pregnant woman has trisomy 21, trisomy 18, and trisomy 13 syndrome. If these three conditions exist, the child will be born with mental retardation, which is not only painful for the child, but also a certain burden on society. So what department should I go to for non-invasive DNA testing?

What department should I go to for non-invasive DNA test?

Non-invasive DNA testing is done in the obstetrics department. Non-invasive prenatal genetic testing is done by collecting peripheral blood (5 ml) from pregnant women, extracting free DNA, using a new generation of high-throughput sequencing technology, and combining it with bioinformatics analysis to determine the risk of the fetus suffering from chromosomal aneuploidy (trisomy 21, also known as Down syndrome, trisomy 18, trisomy 13). The best detection time for this method is in the early and middle stages of pregnancy. It has the characteristics of non-invasive sampling, no risk of miscarriage, high sensitivity, and high accuracy.

Studies have found that fetal free DNA can be detected in the peripheral blood of pregnant women starting from the 4th week of pregnancy. As the gestational age increases, the content of fetal free DNA also increases. After 12 weeks of pregnancy, by drawing peripheral blood from the pregnant woman and extracting fetal free DNA from it, using new-generation gene sequencing technology combined with bioinformatics analysis methods, it is possible to accurately determine whether the fetus has a chromosomal disease.

The traditional serological screening method calculates the results based on parameters such as the pregnant woman's age, gestational age, hormone levels, and weight. It has a high false positive rate and a greater risk of missed detection.

Traditional prenatal diagnosis uses invasive sampling methods, such as chorionic villus sampling, amniocentesis, and fetal umbilical vein puncture. Although these operations can confirm whether the fetus has chromosomal aneuploidy, the puncture wound may cause infection and a certain chance of miscarriage.

Timing of non-invasive prenatal DNA testing

Non-invasive prenatal genetic testing is performed by collecting peripheral blood (5 ml) from pregnant women, extracting free DNA, using a new generation of high-throughput sequencing technology, and combining it with bioinformatics analysis to determine the risk of the fetus suffering from chromosomal aneuploidy (trisomy 21, also known as Down syndrome, trisomy 18, trisomy 13). The best detection time for this method is in the early and middle stages of pregnancy. It has the characteristics of non-invasive sampling, no risk of miscarriage, high sensitivity, and high accuracy.

Studies have found that fetal free DNA can be detected in the peripheral blood of pregnant women starting from the 4th week of pregnancy. As the gestational age increases, the content of fetal free DNA also increases. After 12 weeks of pregnancy, by drawing peripheral blood from the pregnant woman and extracting fetal free DNA from it, using new-generation gene sequencing technology combined with bioinformatics analysis methods, it is possible to accurately determine whether the fetus has a chromosomal disease.

The blood drawing method for non-invasive prenatal testing is the same as the conventional venous blood drawing method, and 5 mL of venous blood is collected for testing. Blood collection does not require fasting or prior examination, as long as you have a normal diet and daily routine.

After blood collection, the test results can be obtained through laboratory testing and bioinformatics data analysis. After receiving the notification, please go to the sampling hospital to collect the test report. The doctor will explain the report results and provide genetic counseling to you.